Email Updates

You are here

Home»Media

AVAC in the News

  • AVAC Condemnation of Uganda’s Anti-Homosexuality Bill 2023

    This week, Ugandan Parliamant took steps toward implementing an anti-gay policy change that would further criminalize and endanger the lives of LGBTQIA+ people. AVAC condemns the proposed legislation and stands in solidarity with the LGBTQIA+ community in Uganda who face threats to their lives, draconian prison terms, and even the prospect of death sentences if this legislation goes forward.

    March 24, 2023
    General
    AVAC

  • ‘Revolutionary’ HIV Prevention Jab Set to Expand Choices for Consumers

    Researchers quickly recognized the potential of the long-term HIV prevention injectable. One of the key studies on the efficacy of the drug — which is a form of PrEP, used to prevent HIV infections — finished months ahead of schedule, as initial results showed the superiority of the injectable to a daily oral version of PrEP. CAB-LA only requires people to receive injections eight weeks apart after an introductory period.

    March 1, 2023
    Devex

  • Take as Needed: Preventing HIV might one day be as easy as using this suppository

    A small study conducted among 23 HIV-negative men and women in the United States has found that a quick-dissolving rectal suppository – no bigger than a fingernail – that contains two antiretroviral drugs is safe, researchers announced at the Conference on Retroviruses and Opportunistic Infections (CROI).

    February 22, 2023
    Spotlight

  • The Next Phase of the Global HIV/AIDs Fight

    The President's Emergency Plan for AIDS Relief — the biggest effort by one nation to address a particular disease — is hitting a milestone anniversary. But advocates worry the US may take its foot off the gas. Why it matters: 20 years after then-President George W. Bush launched PEPFAR in his 2003 State of the Union address, the $7 billion-a-year program is up for reauthorization in Congress.

    February 21, 2023
    General
    Axios

  • Africa CDC Criticizes Exclusion from Pandemic Fund

    The Africa Centres for Disease Control and Prevention said its inability to serve as an “implementing entity” for the new Pandemic Fund cripples its ability to protect the health of African citizens. The Pandemic Fund, which is hosted by the World Bank, and is led from a technical standpoint by the World Health Organization, is a pool of public and private financing aimed at helping low- and middle-income countries in pandemic preparedness and response.

    February 15, 2023
    General
    Devex

  • Still Much To Do

    AVAC looks ahead with Anthony Fauci, MD, to what’s next in the fight against HIV and COVID-19. Prior to his departure as head of the national institute of Allergy and Infectious Diseases (NIAID) at the National Institutes of Health (NIH), Anthony Fauci, MD, spoke with Mitchell Warren, executive director of AVAC, on November 28, 2022, in advance of World AIDS Day. In the interview, they discuss what has been accomplished so far in the fight against HIV and COVID-19 and what’s ahead for Fauci and pandemic preparedness. Below is an edited excerpt.

    February 13, 2023
    General
    POZ Magazine

  • Decriminalization of Sex Work Can Help Prevent HIV

    South Africa has a deep history of pain, rooted in gross human rights violations under the apartheid regime. The preamble to the South African Constitution of 1996 identifies human rights, equality and freedom as founding democratic values of South African society. As a young woman, legal scholar, and sex worker advocate, it is heart wrenching to see that even beyond 1996, we still have laws in place which allow for discrimination, stigmatisation, and violence against certain members of society.

    January 27, 2023
    General
    Health-e News

  • The Only Late-Stage HIV Vaccine Study (Mosaico) Just Tanked. What’s Next?

    It was the big, sad HIV news of mid-January: Janssen Pharmaceuticals’ Mosaico study of an experimental HIV vaccine―which included nearly 4,000 gay men and transgender people in Latin America, the US, and Europe―was coming to a halt because the vaccine was a dud. Though exact numbers have yet to be released, we will likely soon learn that this was determined by the fact that HIV transmission rates in the study’s two arms—vaccine and placebo, with people having the option of being on PrEP in both arms—were basically the same; meaning that the vaccine was showing no efficacy.

    January 25, 2023
    HIV Vaccine
    TheBody

  • Fauci in Context: A BreakingMED Special Feature

    As the fabled ball dropped on Times Square at the stroke of midnight Dec. 31, 2022, it signaled not just the birth of a new year, but also the end of an era—the Fauci era. On Nov. 2, 1984, Anthony Stephen Fauci, MD, was appointed director of the National Institute of Allergy and Infectious Diseases (NIAID). On Dec. 31, after 13,939 days in office, he stepped down. Those 38 years, one month, and 30 days made him the longest-serving director of any of the 27 institutes and centers that comprise the National Institutes of Health (NIH).

    January 25, 2023
    General
    Breaking Med

  • Closure of HIV Vaccine Study Shows How Far We Have To Go

    Janssen pharmaceuticals, the research branch of Johnson & Johnson, said yesterday that they were "disappointed" that the latest HIV candidate vaccine, and the only one left in a phase III efficacy trial, had failed to reach pre-specified standards of efficacy. For this reason, they had terminated the Mosaico Study, which gave the vaccine or a placebo to 3,900 cis and trans gay and bisexual men and trans women in the Americas and Europe.

    January 19, 2023
    HIV Vaccine
    aidsmap

Pages